IDEX Corporation today announced the appointment of Mark A. Buthman to the company’s Board of Directors.
“We are delighted to welcome Mark to our Board of Directors,” said IDEX Chairman and Chief Executive Officer, Andrew Silvernail. “His experience as a Chief Financial Officer of a Fortune 150 company with significant international operations and as a public company director will be a tremendous asset to IDEX. Mark is a disciplined financial leader with a track record of allocating capital in shareholder–friendly ways and his insight will be extremely valuable to our Board and management.”
Mr. Buthman retired from Kimberly–Clark Corporation in 2015, where he was Executive Vice President and Chief Financial Officer from January 2003 to April 2015. During his 33–year career at Kimberly–Clark, Mr. Buthman held a wide range of leadership roles and was part of an executive team that created more than $20 billion in shareholder value since the end of 2002. Mr. Buthman has served since 2011 as a director of West Pharmaceutical Services, Inc., a manufacturer of components and systems for the pharmaceutical, healthcare and consumer products industries.
Mr. Buthman graduated from the University of Iowa in 1981 with a degree in finance and business.
This equipment will significantly lower the site’s CO2 emissions, reduce flaring and save around 60 gigawatt hours (GWh) energy each year. Project kick-off is in February 2021, with completion planned for 2023.
The acquisition significantly strengthens and expands Grace’s existing pharma portfolio. Pharma & Consumer is the largest, fastest growing and most profitable subsegment within Grace’s Materials Technologies business.
Solvay says it has decided to organize its soda ash and derivatives business into a separate and fully controlled legal structure.